MicroVention, a US subsidiary of Japan-based medical device firm Terumo, has reported a positive outcome from the GREAT trial of its 2nd generation HydroCoil embolic system coils in the treatment of patients with an aneurysm.

The HydroCoil embolic system includes a non-bioactive, inert hydrogel core that generates a stable, mechanical platform for natural tissue proliferation and long-term aneurysm occlusion, by absorbing water from the blood and surrounding tissue.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The results from the trial indicated that the embolic system has met the primary and secondary endpoints.

"This independent study showed that hydrogel technology reduces a composite of adverse events, retreatments, morbidity and mortality compared to traditional bare platinum coils."

The prospective, randomised, controlled GREAT (German Randomised Endovascular Aneurysm Trial) trial evaluated the system in 513 patients at 22 hospitals in France and Germany.

The trial's principal investigator Professor Christian Taschner said: "I was intrigued by the opportunity to test whether MicroVention's unique hydrogel technology can improve patient outcomes in a wide-range of aneurysms.

"We are pleased that this independent study showed that hydrogel technology reduces a composite of adverse events, retreatments, morbidity and mortality compared to traditional bare platinum coils."

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The primary endpoint of the trial was the statistically significant decrease in adverse composite outcomes in the patients treated with the embolic system, when compared to bare platinum coils.

The adverse event primary endpoint was a composite of major aneurysm recurrence at 18 months, retreatment at 18 months, morbidity preventing angiographic follow-up and all deaths regardless of cause.

The medium-sized (4mm to12mm) ruptured and unruptured intracranial aneurysms were treated using a minimum of 50% hydrogel coils by length or all bare platinum coils.

HydroFrame, HydroFill and HydroSoft embolic coils can be used alone or in combination with bare platinum coils to embolise various aneurysms and neurovascular lesions.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Awarded for Innovation in Remote Hearing Diagnostics , hearX’s Self Test Kit (STK) delivers clinically validated audiometry via smart devices, enabling remote, scalable hearing assessments in homes, clinics and retail. Learn how hearX is redefining hearing care delivery and reducing costs for providers globally.

Discover the Impact